Live Quote · NASDAQGLUEHealthcare· Biotechnology

Monte Rosa Therapeutics, Inc.

$24.21 0.79%(+$0.19)
TickerSpark Score
77/100
Solid
60
Valuation
40
Profitability
100
Growth
84
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLUE research report →

52-Week Range93% of range
Low
$4.12
Current
$24.21
High
$25.77
Company Overviewwww.monterosatx.com

About the company

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins.

CEO
Markus Warmuth
IPO
2021
Employees
142
HQ
Boston, MA, US

Price Chart

+411.84% · this period
$25.31$14.75$4.19Jul 02Dec 31Jul 02
Valuation
Market Cap
$1.58B
P/E
-13.02
P/S
36.71
P/B
3.04
EV/EBITDA
-11.78
Div Yield
0.00%
Profitability
Gross Margin
95.28%
Op Margin
-345.21%
Net Margin
-302.69%
ROE
-40.99%
ROIC
-21.82%
Growth & Income
Revenue
$123.67M · 63.54%
Net Income
$-38,626,000 · 46.87%
EPS
$-0.46 · 53.06%
Op Income
$-54,208,000
FCF YoY
-172.35%
Performance & Tape
52W High
$25.77
52W Low
$4.12
50D MA
$19.33
200D MA
$16.62
Beta
1.60
Avg Volume
1.10M

Get TickerSpark's AI analysis on GLUE

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 30, 26Janku Filipother5,407
Jun 30, 26Janku Filipother5,407
Jun 30, 26Janku Filipsell5,407
Jun 29, 26Janku Filipother6,000
Jun 29, 26Janku Filipother6,000
Jun 29, 26Janku Filipsell6,000
Jun 29, 26Manning Anthony M.other10,000
Jun 29, 26Manning Anthony M.other10,000
Jun 29, 26Manning Anthony M.sell10,000
Jun 23, 26Janku Filipother6,000
Coverage · GLUE

Our GLUE coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on GLUE yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate GLUE report →
Internal Compare

Similar companies

Peers in the same neighborhood.